Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Overview of attention for article published in Journal of Hematology & Oncology, July 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 31 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 3,705 followers.

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-... https://t.co/zjOUKHKvUU

10 Sep 2021

Reply Repost Favourite

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study #lymphoma #lymsm https://t.co/qNbGxCZJc8

18 Jul 2021

Reply Repost Favourite

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study #lymphoma #lymsm https://t.co/tI9jG3IFVo

17 Jul 2021

Reply Repost Favourite

New article: Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study https://t.co/qDSvX3WqGX #DLBCL #lymsm #hematology https://t.co/29DJUwvWAL

17 Jul 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.